Epidemiology Series Forecast Report on Dyslipidaemia in 12 Major Markets
Dyslipidaemia is defined as an abnormal amount of lipid(s) (triglycerides (>200), Low Density Lipoproteins (LDL) (>130), cholesterol (>240mg/dL) and High Density Lipoproteins (HDL) (<40mg/dL male / <50mg/dL female) within the blood. Many patients meet the requirements of dyslipidaemia on more than one factor.
This report provides the current prevalent population for Dyslipidaemia across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Brazil, Japan, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team , several of the main symptoms and co-morbidities of Dyslipidaemia have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Dyslipidaemia is associated with increased risk of cardiovascular events including:
Stroke
DVT
Metabolic syndrome
Heart failure
T2DM
Atherosclerosis
Peripheral arterial disease
Coronary Artery Disease
Myocardial Infarction
Elevated C-Reactive Protein
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
Able to quantify patient populations in global Dyslipidaemia market to target the development of future products, pricing strategies and launch plans.
Gain further insight into the prevalence of the subdivided types of Dyslipidaemia and identify patient segments with high potential.
Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
Provide a level of understanding on the impact from specific co-morbid conditions on Dyslipidaemia prevalent
Identify sub-populations within Dyslipidaemia which require treatment.
Gain an understanding of the specific markets that have the largest number of Dyslipidaemia patients.
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key comorbid conditions/Features associated with the disease
• Methodology for quantification of patient numbers
• Top-line prevalence for Dyslipidaemia
• Features of Dyslipidaemia patients
o Blood lipid profiles in patients with Dyslipidaemia
o Other risk factors and clinical parameters of Dyslipidaemia patients
o Comorbid conditions of Dyslipidaemic patients
• Abbreviations used in the report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
• Prevalence of Dyslipidaemia, total (000s)
• Prevalence of Dyslipidaemia, males (000s)
• Prevalence of Dyslipidaemia, females (000s)
• Prevalence of Secondary Dyslipidaemia, total (000s)
• BMI Status of patients with Dyslipidaemia, total (000s)
• LDL Status of patients with Dyslipidaemia, total (000s)
• Triglyceride status in patients with Dyslipidaemia, total (000s)
• Dyslipidaemia patients by number of Dyslipidaemias present, total (000s)
• Kidney Function/Stage in patients with Dyslipidaemia, total (000s)
• Blood Pressure Risk Group of patients with Dyslipidaemia, total (000s)
• Dyslipidaemia patients with Diabetes, total (000s)
• Dyslipidaemia patients with Hypertension, total (000s)
• Dyslipidaemia patients with CHF, total (000s)
• Dyslipidaemia patients with CAD, total (000s)
• Dyslipidaemia patients with history of MI, total (000s)
• Dyslipidaemia patients with history of Stroke, total (000s)
• Dyslipidaemia patients with Elevated CRP, total (000s)
• Dyslipidaemia patients with Waist circumference (male >102cm, female >88cm), total (000s)
• Abbreviations and Acronyms used in the report
• USA Prevalence of Dyslipidaemia by 5-yr age cohort, males (000s)
• USA Prevalence of Dyslipidaemia by 5-yr age cohort, females (000s)
• Canada Prevalence of Dyslipidaemia by 5-yr age cohort, males (000s)
• Canada Prevalence of Dyslipidaemia by 5-yr age cohort, females (000s)
• France Prevalence of Dyslipidaemia by 5-yr age cohort, males (000s)
• France Prevalence of Dyslipidaemia by 5-yr age cohort, females (000s)
• Germany Prevalence of Dyslipidaemia by 5-yr age cohort, males (000s)
• Germany Prevalence of Dyslipidaemia by 5-yr age cohort, females (000s)
• Russia Prevalence of Dyslipidaemia by 5-yr age cohort, males (000s)
• Russia Prevalence of Dyslipidaemia by 5-yr age cohort, females (000s)
• Italy Prevalence of Dyslipidaemia by 5-yr age cohort, males (000s)
• Italy Prevalence of Dyslipidaemia by 5-yr age cohort, females (000s)
• Spain Prevalence of Dyslipidaemia by 5-yr age cohort, males (000s)
• Spain Prevalence of Dyslipidaemia by 5-yr age cohort, females (000s)
• UK Prevalence of Dyslipidaemia by 5-yr age cohort, males (000s)
• UK Prevalence of Dyslipidaemia by 5-yr age cohort, females (000s)
• Brazil Prevalence of Dyslipidaemia by 5-yr age cohort, males (000s)
• Brazil Prevalence of Dyslipidaemia by 5-yr age cohort, females (000s)
• Japan Prevalence of Dyslipidaemia by 5-yr age cohort, males (000s)
• Japan Prevalence of Dyslipidaemia by 5-yr age cohort, females (000s)
• India Prevalence of Dyslipidaemia by 5-yr age cohort, males (000s)
• India Prevalence of Dyslipidaemia by 5-yr age cohort, females (000s)
• China Prevalence of Dyslipidaemia by 5-yr age cohort, males (000s)
• China Prevalence of Dyslipidaemia by 5-yr age cohort, females (000s)
+1 888 709 8757
Chat With Us